Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics IL-31 Prior Auth Coverage | Ope…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    IL-31 Inhibitors Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization, renewal, and quantity-limit requirements for Nemluvio (nemolizumab-ilto) subcutaneous autoinjector therapy under the Boeing commercial formulary, including prurigo nodularis, moderate-to-severe atopic dermatitis, and other supported indications.

    Policy Summary
    PayerPrime Therapeutics
    PolicyIL-31 Inhibitors Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing a qualifying indication and satisfaction of the applicable clinical criteria for Nemluvio.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    NemluvioTarget agent
    30 mgStrength
    1 pen/28 daysQuantity limit
    12 monthsApproval length

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥20 lesions
    PN threshold
    16 weeksAD checkpoint

    Coverage Criteria

    Initial Therapy — General Requirements

    Covered for initial therapy when the patient meets the applicable indication pathway and all general requirements below.

    ALL of the following

    • ONE of the following indication pathways

      • Prurigo nodularis pathway

        • The patient has a diagnosis of prurigo nodularis (PN).
      • Moderate-to-severe atopic dermatitis pathway

        • The patient has a diagnosis of moderate-to-severe atopic dermatitis (AD).
      • Other supported indication pathway

        • The patient has another FDA-labeled indication for the requested agent and route of administration, or an indication supported in compendia for the requested agent and route of administration.
    • If the requested indication is FDA labeled, ONE of the following

      • The patient's age is within FDA labeling for the requested indication and requested agent.
      • There is support for using the requested agent for the patient's age for the requested indication.
      • The indication is supported in compendia for the requested agent and route of administration.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, dermatologist, or immunologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • ONE of the following concomitant-use pathways

      • The patient will not be using the requested agent in combination with another immunomodulatory agent (e.g., TNF inhibitor, JAK inhibitor, or IL-4 inhibitor).
      • ALL of the following

        • The patient will be using the requested agent in combination with another immunomodulatory agent.
        • The prescribing information for the requested agent does not limit use with another immunomodulatory agent.
        • There is support for use of combination therapy; a submitted copy of clinical trials, phase III studies, or guidelines is required.
    • The patient does not have any FDA-labeled contraindications to the requested agent.

    Initial Therapy — Prurigo Nodularis

    For initial therapy for prurigo nodularis, ALL of the following must be met.

    ALL of the following

    • The patient has a diagnosis of prurigo nodularis (PN) with all of the following disease features:
    • ALL of the following

      • Presence of at least 20 firm, nodular lesions.
      • Pruritus that has lasted for at least 6 weeks.
      • History and/or signs of repeated scratching, picking, or rubbing.
    • ONE of the following treatment-history pathways

    Initial Therapy — Moderate-to-Severe Atopic Dermatitis

    For initial therapy for moderate-to-severe atopic dermatitis, ALL of the applicable requirements must be met.

    ALL of the following

    • The patient has a diagnosis of moderate-to-severe atopic dermatitis (AD).
    • ONE severity pathway

      • At least 10% body-surface-area involvement.
      • Involvement of body sites that are difficult to treat with prolonged topical corticosteroid therapy (e.g., hands, feet, face, neck, scalp, genitals/groin, or skin folds).
      • Eczema Area and Severity Index (EASI) score greater than or equal to 16.
      • Investigator Global Assessment (IGA) score greater than or equal to 3.

    Renewal Therapy

    Renewal therapy is covered when ALL of the following are met.

    ALL of the following

    • The patient was previously approved for the requested agent through the plan's prior authorization process. Patients not previously approved require initial evaluation review.
    • The patient has had clinical benefit with the requested agent.
    • If the patient has moderate-to-severe atopic dermatitis, ONE of the following

      • The patient is initiating or restarting therapy with the requested agent.
      • The patient has been treated with the requested agent for less than 16 consecutive weeks.
      • ALL of the following

    Nemluvio Loading and Maintenance Dosing

    Nemluvio loading and maintenance dosing is handled as follows.

    ALL of the following

    • If approving the initial loading dose of Nemluvio for atopic dermatitis or prurigo nodularis, approve the quantity for the loading dose for 1 month per FDA labeling.
    • After the loading-dose period, approve the maintenance dose for the remainder of the approval period.
    • Maintenance dosing begins 4 weeks after the patient receives the loading dose.

    The requested agent should not be used in combination with another immunomodulatory agent (e.g., TNF inhibitors, JAK inhibitors, or IL-4 inhibitors) unless the prescribing information for the requested agent does not limit combination use and there is support for the combination therapy. A submitted copy of clinical trials, phase III studies, or guidelines is required to support combination therapy.

    Clinical Thresholds and Checkpoints

    Prurigo nodularis lesion count
    Required lesion countAt least 20 firm, nodular lesions
    ConditionPrurigo nodularis (PN)
    Additional PN featuresPruritus lasting at least 6 weeks and a history or signs of repeated scratching, picking, or rubbing
    Prurigo nodularis pruritus duration
    Required durationAt least 6 weeks
    SymptomPruritus associated with prurigo nodularis
    Additional PN featuresAt least 20 firm, nodular lesions and a history or signs of repeated scratching, picking, or rubbing

    Authorization, Documentation, and Denial Conditions

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for the requested IL-31 inhibitor. Submit an initial authorization demonstrating that the applicable diagnosis, severity or clinical features, prior-treatment requirements, prescriber qualifications, concomitant-therapy requirements, and FDA-labeling or compendia criteria are met.

    • Approval is generally limited to 12 months.
    • The requested agent must be appropriate for the patient's diagnosis and route of administration, with age supported by FDA labeling or other applicable evidence.
    • The prescriber must be a specialist in the patient's diagnosis, or must have consulted with an appropriate specialist.
    • The patient must not have an FDA-labeled contraindication to the requested agent.
    Prior Authorization

    Renewal Prior Authorization

    Submit a renewal prior authorization before the current approval expires. Renewal requires prior approval through the plan's authorization process and documentation that the patient has experienced clinical benefit with the requested agent.

    Policy Background

    Nemluvio (nemolizumab-ilto) is an IL-31 inhibitor administered by subcutaneous injection using an autoinjector. The policy covers its use for specified inflammatory pruritic skin diseases, primarily prurigo nodularis and moderate-to-severe atopic dermatitis, as well as other FDA-labeled or compendia-supported indications when applicable clinical and authorization requirements are met.

    Key Definitions

    Prurigo nodularis (PN)
    Lesion characteristicAt least 20 firm, nodular lesions
    Pruritus characteristicPruritus lasting at least 6 weeks
    Behavioral featureA history or signs of repeated scratching, picking, or rubbing
    Moderate-to-severe atopic dermatitis (AD)
    Body-surface-area criterionAt least 10% involvement
    Severity criteriaDifficult-to-treat sites, EASI score at least 16, or IGA score at least 3
    Treatment-response characteristics

    Nemluvio Initial Authorization

    Nemluvio Initial Authorization

    Initial Nemluvio therapy requires a qualifying indication and all applicable authorization conditions.

    Initial Nemluvio authorization

    • Qualifying indication

      • The patient meets the policy criteria for prurigo nodularis.
      • The patient meets the policy criteria for moderate-to-severe atopic dermatitis.
      • The requested agent and route are supported for another FDA-labeled indication.
      • The requested agent and route are supported for a compendia-supported indication.

    Nemluvio Renewal

    Nemluvio Renewal

    Nemluvio will be approved for renewal when all of the following continuation criteria are met.

    Nemluvio renewal

    • The patient was previously approved for Nemluvio through the plan's prior authorization process.

      Patients without prior approval require initial evaluation.

    • The patient has had clinical benefit with Nemluvio.
    • Atopic dermatitis treatment-duration pathway, when applicable

      • The patient is initiating or restarting Nemluvio.
      • The patient has been treated with Nemluvio for less than 16 consecutive weeks.

    Required Prior Therapies

    StepIndicationRequired trialExceptions
    1Prurigo nodularisTry one medium-potency topical corticosteroid for at least 2 weeks and document an inadequate response.The trial is not required if the patient has intolerance or hypersensitivity to one medium-potency topical corticosteroid; an FDA-labeled contraindication to all medium-, high-, and super-potency topical corticosteroids; or medication history, excluding samples, showing use of a biologic immunomodulator or systemic targeted synthetic small molecule drug that is FDA-labeled or compendia-supported for prurigo nodularis.
    StepIndicationRequired trialExceptions
    1Moderate-to-severe atopic dermatitisTry one medium-potency topical corticosteroid for at least 4 weeks and document an inadequate response.The trial is not required if the patient has intolerance or hypersensitivity to one medium-potency topical corticosteroid; an FDA-labeled contraindication to all medium-, high-, and super-potency topical corticosteroids; or medication history, excluding samples, showing use of a biologic immunomodulator or systemic targeted synthetic small molecule drug that is FDA-labeled or compendia-supported for atopic dermatitis.
    StepIndicationRequired trialExceptions
    2Moderate-to-severe atopic dermatitisTry one topical calcineurin inhibitor, such as pimecrolimus or tacrolimus, for at least 6 weeks and document an inadequate response.The trial is not required if the patient has intolerance or hypersensitivity to one topical calcineurin inhibitor; an FDA-labeled contraindication to all topical calcineurin inhibitors; or medication history, excluding samples, showing use of a biologic immunomodulator or systemic targeted synthetic small molecule drug that is FDA-labeled or compendia-supported for atopic dermatitis.

    Nemluvio Quantity Limit

    Nemluvio 30 mg pen
    Program quantity limit1 pen per 28 days
    ProductNemluvio 30 mg pen
    Loading-dose exceptionFor an initial loading dose for atopic dermatitis or prurigo nodularis, approve the loading-dose quantity for 1 month per FDA labeling; maintenance dosing begins 4 weeks later
    Policy Summary
    PayerPrime Therapeutics
    PolicyIL-31 Inhibitors Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing a qualifying indication and satisfaction of the applicable clinical criteria for Nemluvio.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and CheckpointsAuthorization, Documentation, and Denial ConditionsPolicy BackgroundKey DefinitionsNemluvio Initial AuthorizationNemluvio RenewalRequired Prior TherapiesNemluvio Quantity Limit
    Tried and had an inadequate response to one at least medium-potency topical corticosteroid used in the treatment of PN after at least 2 weeks of therapy.
  1. Has an intolerance or hypersensitivity to one at least medium-potency topical corticosteroid used in the treatment of PN.
  2. Has an FDA-labeled contraindication to all medium-, high-, and super-potency topical corticosteroids used in the treatment of PN.
  3. Medication history, excluding sample use, indicates use of a biologic immunomodulator agent or systemic targeted synthetic small-molecule drug (e.g., oral JAK inhibitor) that is FDA labeled or supported in compendia for treatment of PN.
  4. ONE treatment-history pathway

    • Topical corticosteroid pathway

      • Tried and had an inadequate response to one at least medium-potency topical corticosteroid used in the treatment of AD after at least 4 weeks of therapy.
      • Has an intolerance or hypersensitivity to one at least medium-potency topical corticosteroid used in the treatment of AD.
      • Has an FDA-labeled contraindication to all medium-, high-, and super-potency topical corticosteroids used in the treatment of AD.
    • Topical calcineurin inhibitor pathway

      • Tried and had an inadequate response to one topical calcineurin inhibitor (e.g., pimecrolimus or tacrolimus) used in the treatment of AD after at least 6 weeks of therapy.
      • Has an intolerance or hypersensitivity to one topical calcineurin inhibitor used in the treatment of AD.
      • Has an FDA-labeled contraindication to all topical calcineurin inhibitors used in the treatment of AD.
    • Medication history, excluding sample use, indicates use of a biologic immunomodulator agent or systemic targeted synthetic small-molecule drug (e.g., oral JAK inhibitor) that is FDA labeled or supported in compendia for treatment of AD.
    • The patient has another FDA-labeled indication for the requested agent and route of administration, or an indication supported in compendia for the requested agent and route of administration.
  5. ONE topical-therapy pathway

    • The patient will use topical corticosteroid or topical calcineurin inhibitor therapy in combination with the requested agent.
    • The patient is currently treated with the requested agent, and concurrent topical therapies (topical corticosteroid or topical calcineurin inhibitor) have been discontinued because of sufficient improvement in AD.
    • The patient has an intolerance, hypersensitivity, or FDA-labeled contraindication to all topical corticosteroids and topical calcineurin inhibitors.
  6. ONE treatment-timing pathway

    • The patient is initiating or restarting therapy with the requested agent.
    • The patient has been treated with the requested agent for less than 16 consecutive weeks.
    • ALL of the following

      • The patient has been treated with the requested agent for at least 16 consecutive weeks.
      • ANY of the following

        • The requested maintenance dose is 30 mg every 8 weeks.
        • The patient has not achieved and maintained clear or almost clear skin.
        • There is support for continued therapy at the requested maintenance dose.
  7. The patient has been treated with the requested agent for at least 16 consecutive weeks.
  8. ANY of the following

    • The requested maintenance dose is 30 mg every 8 weeks.
    • The patient has not achieved and maintained clear or almost clear skin.
    • There is support for continued therapy at the requested maintenance dose.
  9. The prescriber is a specialist in the area of the patient's diagnosis (e.g., allergist, dermatologist, or immunologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
  10. ONE of the following concomitant-use pathways

    • The patient will not be using the requested agent in combination with another immunomodulatory agent (e.g., TNF inhibitor, JAK inhibitor, or IL-4 inhibitor).
    • ALL of the following

      • The patient will be using the requested agent in combination with another immunomodulatory agent.
      • The prescribing information for the requested agent does not limit use with another immunomodulatory agent.
      • There is support for use of combination therapy; a submitted copy of clinical trials, phase III studies, or guidelines is required.
  11. The patient does not have any FDA-labeled contraindications to the requested agent.
  12. Atopic dermatitis body-surface area
    Required involvementAt least 10% body-surface-area involvement
    ConditionModerate-to-severe atopic dermatitis
    Alternative severity featuresDifficult-to-treat body-site involvement, EASI score at least 16, or IGA score at least 3
    Eczema Area and Severity Index
    Required scoreEASI greater than or equal to 16
    MeasureEczema Area and Severity Index
    ConditionModerate-to-severe atopic dermatitis
    Investigator Global Assessment
    Required scoreIGA greater than or equal to 3
    MeasureInvestigator Global Assessment
    ConditionModerate-to-severe atopic dermatitis
    Atopic dermatitis treatment checkpoint
    Treatment checkpoint16 consecutive weeks
    Applies toModerate-to-severe atopic dermatitis treatment with the requested agent
    Post-checkpoint pathwayThe maintenance dose is 30 mg every 8 weeks, clear or almost clear skin has not been achieved and maintained, or continued therapy at the requested maintenance dose is supported
    • For moderate-to-severe atopic dermatitis, include the applicable treatment-duration, maintenance-dose, disease-control, specialist, and concomitant-therapy requirements.
    • Renewal approval is generally limited to 12 months.
    • The patient must not have an FDA-labeled contraindication to the requested agent.
    Prior Authorization

    Quantity-Limit Authorization

    A quantity-limit authorization is required when the requested dose exceeds the program quantity limit. Submit the dose, indication, and supporting rationale for the requested quantity.

    • Quantities within the program limit may be approved when other authorization criteria are met.
    • For a quantity above the limit, document support for the higher dose for the requested indication, and ensure the dose does not exceed the maximum FDA-labeled dose.
    • If using a higher-strength product to remain within the limit, document why the requested quantity cannot be achieved with a lower quantity of the higher strength.
    • For Nemluvio loading doses in atopic dermatitis or prurigo nodularis, the loading quantity may be approved for 1 month, followed by maintenance dosing; maintenance begins 4 weeks after the loading dose.
    • Quantity-limit approval is generally limited to 12 months.
    Step Therapy

    Prurigo Nodularis Topical Therapy

    For prurigo nodularis, document the required topical corticosteroid step before requesting the agent, unless the patient meets an exception. The record must show inadequate response, intolerance or hypersensitivity, or an FDA-labeled contraindication to the applicable topical corticosteroids.

    • Document at least 20 firm, nodular lesions, pruritus lasting at least 6 weeks, and repeated scratching, picking, or rubbing.
    • Document an inadequate response to at least one medium-potency topical corticosteroid after at least 2 weeks of treatment; alternatively document intolerance or hypersensitivity, or an FDA-labeled contraindication to all medium-, high-, and super-potency topical corticosteroids used for PN.
    • A prior biologic immunomodulator or systemic targeted synthetic small-molecule drug supported for PN may satisfy the applicable prior-treatment pathway.
    Step Therapy

    Atopic Dermatitis Topical Therapy

    For moderate-to-severe atopic dermatitis, document the required topical corticosteroid trial before requesting the agent, unless an exception applies. The record must show inadequate response, intolerance or hypersensitivity, or an FDA-labeled contraindication to the applicable topical corticosteroids.

    • Document at least 10% body-surface-area involvement, difficult-to-treat sites, an EASI score of at least 16, or an IGA score of at least 3.
    • Document an inadequate response to at least one medium-potency topical corticosteroid after at least 4 weeks of treatment; alternatively document intolerance or hypersensitivity, or an FDA-labeled contraindication to all medium-, high-, and super-potency topical corticosteroids used for AD.
    • The applicable AD pathway may also require a topical calcineurin-inhibitor trial, intolerance or hypersensitivity, or an FDA-labeled contraindication to all topical calcineurin inhibitors.
    • A prior biologic immunomodulator or systemic targeted synthetic small-molecule drug supported for AD may satisfy the applicable prior-treatment pathway.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Inadequate response, intolerance, hypersensitivity, or contraindication involving applicable topical corticosteroid or topical calcineurin inhibitor therapy; prior supported biologic or systemic targeted therapy may also satisfy the pathway
    Compendia allowed
    AHFSAHFS
    DrugDexLevel 1, 2a, or 2b evidence
    NCCNLevel 1, 2a, or 2b recommended use

    Age support when an FDA-labeled indication is used

    • The patient's age is within FDA labeling for the requested indication.
    • There is support for use of the requested agent for the patient's age and indication.
  13. The prescriber is a specialist in the area of the patient's diagnosis, or has consulted with an appropriate specialist.
  14. Concomitant immunomodulator therapy

    • Nemluvio will not be used in combination with another immunomodulatory agent.
    • If combination therapy is used, Nemluvio prescribing information does not limit such use and supporting clinical trials, phase III studies, or guidelines are submitted.
  15. The patient does not have an FDA-labeled contraindication to Nemluvio.
  16. <16 consecutive weeks
  17. At least 16 weeks of therapy

    • The patient has been treated with Nemluvio for at least 16 consecutive weeks.≥16 consecutive weeks
    • Ongoing-treatment condition

      • The requested maintenance dose is 30 mg every 8 weeks.
      • The patient has not achieved and maintained clear or almost clear skin.
      • There is support for continued therapy at the requested maintenance dose.
  18. The prescriber is a specialist in the area of the patient's diagnosis, or has consulted with an appropriate specialist.
  19. Concomitant immunomodulator therapy

    • Nemluvio will not be used in combination with another immunomodulatory agent.
    • If combination therapy is used, Nemluvio prescribing information does not limit such use and supporting clinical trials, phase III studies, or guidelines are submitted.
  20. The patient does not have an FDA-labeled contraindication to Nemluvio.